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Abstract This study investigated the ETA and ETz receptor 
subtypes in rat adrenal cortex. The ETA antagonist, BQ-123, 
inhibited the zona glomerulosa (zg), but not the inner zone (iz) 
response to ET-l. RES-701-1, the ETz antagonist, abolished the 
iz response to ET-l, but had less effect on the zg. [12sI]ET-1 
binding studies revealed two receptor subtypes in both zones, with 
ETA predominating in the zg, and ETs in the iz. These data 
suggest that the ETA subtype is functionally more important in 
the zg while the ETa receptor is the major subtype in the inner 
zones. 
Key words: Aldosterone; Corticosterone; 
Endothelin receptor; Zona glomerulosa; Adrenal 
1. Introduction 
The potent vasoactive peptide endothelin-1 has been shown 
to stimulate adrenal steroidogenesis in several different mam- 
malian species, including rat, cow and human [l-6]. The ef- 
fects of endothelin have been demonstrated both in vivo and 
in vitro. Furthermore, it has been reported that this peptide is 
synthesised within the adrenal cortex [7], and is released fol- 
lowing stimulation with corticotrophin (ACTH), the major 
regulator of glucocorticoid secretion [2,8]. 
Endothelin acts through two distinct receptor subtypes, des- 
ignated ETA and ETn. The ET* receptor is selective for 
endothelin-1 and is specifically antagonised by BQ-123, while 
the ETa receptor binds both endothelin-1 and the related 
peptide, endothelin-3, and is specifically antagonised by 
RES-701-l. Autoradiographic studies have demonstrated 
high levels of [‘251]ET-1 binding in the adrenal glands from 
several different species, with the highest levels of binding in 
the zona glomerulosa [9%11]. Studies of endothelin receptors 
in the adrenal gland have therefore focussed on this region of 
the gland. The presence of both subtypes has been described 
in the rat adrenal gland [12] and in normal and adenomatous 
human zona glomerulosa tissue but it is not clear which is 
involved in mediating the response to stimulation [7,1 I]. To 
date the nature of the ET receptors in the inner adrenocortical 
zones has not been established. The present study was de- 
signed to investigate the distribution of the ETA and ETr~ 
receptor subtypes in the different zones of the rat adrenal 
cortex, and to determine their functional significance in med- 
iating the adrenocortical response to endothelin stimulation. 
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2. Materials and methods 
2. I. Materials 
All chemicals were obtained from Sigma Chemical Co, Poole, Dor- 
set, UK, with the following exceptions: ACTH(l-24) (Synacthen) and 
angiotensin II amide (Hypertensin) were supplied by Ciba-Geigy, 
Horsham, Sussex, UK; collagenase (Worthington type I) was pur- 
chased from Lorne Diagnostics, Reading, Berks, UK; endothelin 
and BQ-123 were purchased from Peninsula Laboratories Europe 
Ltd, St. Helens, Merseyside, UK; RES-701-l was supplied by Kyowa 
Hakko Kogvo Co. Ltd. Tokvo. Japan. All radiolabels were uurchased 
from Amersham International plc: Amersham, Bucks, UK. ‘Male and 
female Wistar rats, body weight 350-450 g, were obtained from A. 
Tuck and Sons, Battlesbridge, Essex, UK and maintained at Queen 
Mary and Westfield College for a minimum of 5 days prior to use. 
They were fed standard rat chow and water was available ad hbitum. 
2.2. Eflects of endothelin receptor antagonists on steroidogenesis 
Zona glomerulosa and zonae fasciculata/reticularis cells were pre- 
pared by collagenase digestion, as described previously [2]. Zona glo- 
merulosa cells contained less than 10% contamination with inner zone 
cells, while zonae fasciculata/reticularis cells were contaminated with 
less than 5% of zona glomerulosa cells. Cells (5 X lo5 cells/tube) were 
incubated for 60 min at 37°C with lo-’ moY1 ET-l in the absence or 
presence of endothelin antagonists RES-701-I or BQ-123 (IO@ mol/l). 
After incubation the samples were centrifuged at 10000 rpm to pellet 
the cells, and stored at -20°C. Unextracted ahquots were assayed for 
aldosterone (zona glomerulosa cells) and corticosterone (inner zone 
cells) by direct radioimmunoassay as previously described [2]. 
2.3. [‘2”I]ET-I binding assay 
The binding assay was a modified form of previously described 
methods [13,14]. Briefly, aliquots of cells (10” cells/tube) were incu- 
bated (in KRBGA with 20 mM HEPES, 150 mM NaCl and 1 pg/ml 
each of aprotinin and soybean trypsin inhibitor) with 3- 
(f’2”Iliodotvrosv11”)ET-I (2000 Ci/mmol: final concentration 0.1 
nmoi/l) for- 60 min at 37°C. Non-specific binding was determined by 
incubating labelled cells with IOO-fold excess of unlabelled peptide. 
Incubations were terminated by the addition of 800 ~1 of ice-cold 
buffer and the tubes were centrifuged at 10000 rpm for 5 min at 
4°C. Supernatants were discarded and the pellets washed twice. After 
washing, radioactivity bound to the cells was estimated using a 1272 
Clinigamma counter (LKB Wallac, St Albans, Herts, UK). Displace- 
ment studies were carried out using ET-l, BQ-123, RES-701-1, ACTH 
or angiotensin II. 
2.4. Statistical analysis 
Arithmetic means and standard deviations were calculated. One- 
way analysis of variance was used to test whether peptides had a 
significant effect on basal (control) levels of steroids. Student’s t-tests 
were used to test whether the above-mentioned responses were af- 
fected by the presence of antagonists. Saturation data were analysed 
by Hill and Scatchard analysis using the computer programme LI- 
GAND. 
3. Results 
3.1. EfSect of’ endothelins on steroid secretion 
Endothelin-1 caused a significant increase in aldosterone 
secretion by collagenase dispersed zona glomerulosa cells 
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(Fig. 1A). This effect was slightly attenuated by the ETa re- 
ceptor subtype antagonist, RES-701-1 (p < 0.05) and very sig- 
nificantly attenuated in the presence of the ETA receptor an- 
tagonist, BQ-123 (p < 0.001). In the presence of both receptor 
antagonists, ET-l-stimulated aldosterone secretion was not 
significantly different from basal levels (Fig. 1A). Neither of 
these antagonists had any effect on basal or ACTH-stimulated 
aldosterone production (data not shown). 
Fig. 1B illustrates the effects of ET-l on corticosterone 
production by collagenase-dispersed zonae fasciculata/reticu- 
laris cells in the presence or absence of either BQ-123 or RES- 
701-l. In the absence of the antagonists, ET-l (lo-* mol/l) 
caused significant stimulation of corticosterone secretion from 
zonae fasciculata/reticularis cells. The ETA antagonist, BQ- 
123 (10-s mol/l) had no effect on the corticosterone response 
to ET-l. However, lo-* molll RES-701-1 significantly inhib- 
ited the corticosteroid response to ET-l (p < 0.001). The re- 
sponse to the combination of these receptor antagonists on 
endothelin-stimulated corticosterone secretion resulted in a 
further reduction of the ET-l response. Neither antagonist 
had any effect on basal or ACTH-stimulated corticosterone 
secretion (data not shown). 
3.2. Binding studies 
The binding kinetics of [‘251]ET-1 are shown in Fig. 2. 
Binding of ET-l to the zona glomerulosa was saturable at 
75-120 pmol and 175-200 pmol [1251]ET-1 and non-specific 
binding was less than 10% of bound radioactivity (Fig. 2A). 
Binding data were analysed by the curve-fitting programme 
LIGAND and Hill analysis predicted the probability of a 2 
binding site model versus a single population (p < 0.05) of 
endothelin receptors in the rat adrenal zona glomerulosa. Sub- 
sequent Scatchard analysis revealed the presence of 2 popula- 
tions of binding sites (Fig. 2B). One receptor population of 
high-affinity binding sites had an apparent dissociation con- 
stant (&) of 1.87 nmol/l with a concentration of binding sites 
(B,,) of 535 fmol/lO” zona glomerulosa cells (Hill coefficient 
of 0.593). The second population of receptors were low-affin- 
ity binding sites with an apparent & of 10.25 nmolll and a 
B max of 1047 fmol/lO” zona glomerulosa cells (Hill coefficient 
of 0.774). Displacement of [1251]ET-1 binding by unlabelled 
peptides showed that ET-l displaced the tracer in a concen- 
tration-dependent manner with an IC50 of 5 X lo-’ mol/l 
(Fig. 2C). BQ-123, an ETA receptor antagonist, displaced 
[‘251]ET-1 in a dose-dependent manner, similar to that of un- 
labelled ET-l (Fig. 2C). RES-701-1 caused some displacement 
of the labelled ligand, although to a lesser extent than BQ-123 
(Fig. 2C). Neither angiotensin II nor ACTH displaced 
[L2”I]ET-l binding in zona glomerulosa cells. 
The binding kinetics of [‘251]ET-1 in inner zone cells are 
illustrated in Fig. 3. ET-l binding was saturable at 175-200 
pmol [12”I]ET-l (Fig. 3A) and Hill analysis predicted there 
was a single population of endothelin receptors (Hill coeffi- 
cient of 0.943; p< 0.05). The Scatchard plot (Fig. 3B) re- 
vealed a single class of low-affinity binding sites with an ap- 
parent Kd of 4.95 nM and B,,, of 521 fmol/lO’ zonae 
fasciculata/reticularis cells. 
Displacement studies with ET-l, RES-701-1, BQ-123, 
ACTH or angiotensin II revealed a difference in the receptor 
subtype present in this tissue compared to the zona glomer- 
ulosa. In these cells RES-701-1 had a potency comparable to 
ET-l, whereas BQ-123 was not very effective at displacing 
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Fig. 1. Effect of endothelin receptor antagonists on endothelin-stim- 
ulated (lo-* mol/l) steroid secretion. (A) Effects on aldosterone se- 
cretion by zona glomerulosa cells and (B) effects on corticosterone 
secretion by inner zone cells. Effect of lo-* mol/l BQ-123, lo-*mol/l 
RES-701-l or both BQ-123 and-RES-701-l together. Values are 
means f S.E.M., n = 4. ***p < 0.001 compared with control levels of 
aldosterone (analysis of variance). +p < 0.05, +++p < 0.001 compared 
with ET-l alone (Student’s r-test). 
labelled ET-l from the receptor. Neither ACTH nor angio- 
tensin II had any effect on [‘251]ET-1 binding to zonae fasci- 
culata/reticularis cells. 
4. Discussion 
The data presented here strongly suggest that different sub- 
types of the endothelin receptor are expressed in the zona 
glomerulosa and the zonae fasciculata/reticularis of the rat 
adrenal gland. Furthermore, these receptor subtypes appear 
to be functionally important in mediating the responses of the 
different zones to stimulation by endothelin-1. 
The finding that the aldosterone response to endothelin-1 
stimulation was significantly inhibited by both BQ-123 and 
RES-701-1 strongly suggests that both ET receptor subtypes 
have a role in mediating the zona glomerulosa response to 
endothelin stimulation. As it was shown that BQ-123 had a 
much greater inhibitory effect, it appears likely that the ETA 
receptor plays the major role. This conclusion is supported by 
the receptor binding studies which suggest that of the two 
forms of the endothelin receptor in the zona glomerulosa, 
the most abundant is the ETA subtype. 
As much of the research on the adrenal actions of endothe- 
lin have focused on the effects of this peptide on aldosterone 
secretion, so previous studies have concentrated almost exclu- 
sively on the endothelin receptors in the zona glomerulosa. 
The results of the present investigation confirm the findings 
of other studies which have described both ETA and ETa 
receptor subtypes in both the human and bovine adrenal cor- 
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Fig. 2. Scatchard analysis, saturation curves and inhibition of [‘251]ET-1 binding to zona glomernlosa cells. (A) Concentration dependence of 
[‘251]ET-1 binding to membrane preparations from adrenal zona glomerulosa cells showing specific (0) and non-specific (0) binding. (B) Scatch- 
ard analysis of specific [iz51]ET-1 binding. (C) Inhibition of total [1251]ET-1 binding by increasing concentrations of ET-l (o), BQ-123 (v), 
RES-701-l (0) ACTH (v) or angiotensin II (0). Each point represents the means from two experiments conducted in triplicate. 
tex. Rossi and co-workers [ 1 l] characterised endothelin recep- 
tors in the human adrenal zona glomerulosa. The receptor Kds 
they described are within the same range as those described in 
the present study, although others, notably Vesci et al [15], 
described a receptor with a higher affinity in the rat adrenal. 
The functional significance of the different receptor types in 
the adrenal gland has been unclear. Gomez-Sanchez and co- 
workers [16] reported that the ETA receptor was mainly re- 
sponsible for mediating the aldosterone response in the calf, 
while the same group later found that the ETA antagonist 
BQ123 had no effect on the aldosterone response to endothe- 
lin-1 stimulation in the rat, suggesting that endothelin was 
acting through the ETa receptor in this species [6]. In this 
study, however, Pecci and co-workers removed the adrenals 
from rats treated in vivo, and measured the zona glomerulosa 
content of aldosterone, rather than either the circulating con- 
centration or the subsequent in vitro response. As the rat 
adrenal gland does not store significant amounts of aldoster- 
one the validity of this measurement is questionable. It is not 
clear why the rat adrenal zona glomerulosa would require two 
receptor subtypes to mediate the same response. However, the 
results of the present study strongly suggest that of the two 
endothelin receptor subtypes the ETA receptor mediates the 
steroidogenic effects of endothelin-1 in the zona glomerulosa. 
While the presence of endothelin receptors in the inner 
zones of the adrenal cortex has been clearly demonstrated, 
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Fig. 3. Scatchard analysis, saturation curves and inhibition of [i’“I]ET-1 binding to inner zone cells. (A) Concentration dependence of [iz51]ET- 
1 binding to membrane preparations from adrenal zonae fasciculata/reticularis cells showing specific (0) and non-specific (0) binding. (B) 
Scatchard analysis of specific [‘251]ET-1 binding. (c) Inhibition of total [1251]ET-l binding by increasing concentrations of ET-l (o), BQ-123 
(v)), RES-701-l (o), ACTH (v) or angiotensin II (0). Each point represents the means from two experiments conducted in triplicate. 
no attempt has been made to characterise these receptors. 
Immunohistochemical studies have described the ETn recep- 
tor around the blood vessels of the bovine adrenal cortex, but 
not associated with the steroidogenic cells of the zona glomer- 
ulosa [17]. Using autoradiography, Rossi and co-workers 
demonstrated binding of labelled endothelin to specific recep- 
tors throughout the human adrenal cortex [l 11. They found 
that BQ123 reduced binding in the zona glomerulosa but did 
not significantly attenuate binding in the zona fasciculata. 
This would suggest the presence of significant ETA binding 
in the zona glomerulosa and ETn binding in the inner zones, 
in good agreement with the present study. In previous studies 
we demonstrated a potent effect of endothelin-1 on cortico- 
sterone secretion by dispersed rat adrenal zona fasciculata/ 
reticularis cells [2]. Thus, there is a clear functional signifi- 
cance to the presence of endothelin receptors in the inner 
zones of the rat adrenal cortex. 
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